J&J wins FDA Sustenna nod; EU watchdog takes EMA to task over Humira; Recipharm has acquires Portugals Lusomedicamenta;

@FiercePharma: Top-read special report: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@EricPFierce: ICYMI: Cadilia gets slapped with #FDA warning for not following up on complaints about stinking APIs. More | Follow @EricPFierce

@CarlyHFierce: Why are M&A hedge funds gun shy? Blame AbbVie for killing its Shire deal. Story | Follow @CarlyHFierce

> The FDA has green-lighted Johnson & Johnson's ($JNJ) long-acting antipsychotic Invega Sustenna for schizoaffective disorder. More

> An EU watchdog has taken issue with the EMA over the redaction of clinical study reports for AbbVie's ($ABBV) Humira. Story

> Medecins Sans Frontières' public appeal for Ebola vaccine development in September came months too late, a group veteran says. More

> Sun Pharmaceutical is reworking its deal to buy Ranbaxy Laboratories to address concerns of regulators in India that it will hold too prominent a position there. Story

> Swedish CDMO Recipharm has acquired Portuguese competitor, Lusomedicamenta, in a deal valued at €112.3 million ($140 million.) Release

> Valeant Pharmaceutical ($VRX) has completed a $12 million renovation of its headquarters in Bridgewater, NJ. Release

Medical Device News

@FierceMedDev: Glooko merges tech data to avoid activity-triggered hypoglycemic events. More | Follow @FierceMedDev

@VarunSaxena2: Philips, Duke to collaborate on infant temperature monitoring using InnerSense probe. Article | Follow @VarunSaxena2

@EmilyWFierce: $BSX ordered to pay $26.7M in one of first federal trials over vaginal mesh devices. Story | Follow @EmilyWFierce

> Monteris nabs $30M to grow its less invasive neurosurgery tech. Story

> St. Jude 'looking' to expand production and services operations in Malaysia. More

Biotech News

@FierceBiotech: IPOs: $FGEN comes up big while $NDRM limps out of the gate. Story | Follow @FierceBiotech

@JohnCFierce: Puma drug neratinib flunks PFS, ORR endpoints. Article | Follow @JohnCFierce

@DamianFierce: $GERN rides again as $JNJ partners up on imetelstat for up to $900M. Release | Follow @DamianFierce

> Alexion co-founder will retire in January. Chutes & Ladders

> Boehringer taps WellPoint's outcomes data to develop new a-fib drugs. More

> J&J bets up to $935M that Geron's drug can shake a checkered past. Article

And Finally... A U.S. advisory panel has recommended for the first time to partially strike a long-standing ban preventing gay and bisexual men from donating blood. More

Suggested Articles

A top adviser for the Trump administration is calling on Congress to push for more manufacturing in Puerto Rico. 

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.